Bicara Therapeutics BCAX Business Segments — Interest Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's business segments — interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's business segments — interest income?
- Bicara Therapeutics (BCAX) reported business segments — interest income of $4.08M in Q1 2026.
- How has Bicara Therapeutics's business segments — interest income changed year-over-year?
- Bicara Therapeutics's business segments — interest income decreased by 18.6% year-over-year, from $5.01M to $4.08M.
- What is the long-term trend for Bicara Therapeutics's business segments — interest income?
- Over 2 years (2023 to 2025), Bicara Therapeutics's business segments — interest income has grown at a 268.8% compound annual growth rate (CAGR), from $1.31M to $17.87M.
- What does business segments — interest income mean?
- This metric reflects the revenue earned from cash, cash equivalents, and marketable securities held by the company. For a clinical-stage biopharmaceutical firm, this represents the return on capital raised to fund ongoing research and development programs.